The UK’s medicines regulator has announced a major programme of reforms designed to modernise healthcare regulation, accelerate access to innovative treatments and strengthen
patient safety as artificial intelligence (AI), genomic research and personalised medicine reshape the life sciences sector.
The Medicines and Healthcare products Regulatory Agency (MHRA) published its 2030 Strategy on 14 October 2026, setting out plans to improve regulatory efficiency, expand the use of real-world health data and establish the UK as a leading international destination for developing and introducing new medicines and medical technologies.
The strategy covers patients across England, Scotland, Wales and Northern Ireland. It aims to ensure that scientific advances translate into tangible health benefits while maintaining rigorous standards for the safety, quality and effectiveness of medicines and medical devices.
The agency’s mission is to promote “health and prosperity for all, through scientific excellence”, combining stronger public protection with a more responsive regulatory system that enables patients to benefit from medical innovation sooner.
Faster access to treatments while maintaining safety standards
Minister for Health Innovation James Frith said the government wanted patients to gain earlier access to new medicines and technologies without compromising safety.
He said the strategy would help the MHRA adapt to advances in AI, medical data and pharmaceutical research, while expanding enforcement against illegal medicines. It also places greater emphasis on ensuring that regulation reflects the needs of different patient groups.
Plans to improve representation in clinical trials and introduce a Women’s Health Plan are intended to address gaps in medical evidence and reduce inequalities in healthcare outcomes, including differences affecting women and ethnic minority communities.
MHRA Chief Executive Lawrence Tallon said scientific progress was transforming the prevention, diagnosis and treatment of disease. Cell and gene therapies could offer long-lasting benefits or even cures for some conditions, while precision medicine and advanced diagnostics were creating opportunities for more targeted treatments and earlier intervention.
However, these developments also present challenges for regulators, requiring new approaches to clinical research, evidence assessment, manufacturing oversight and the monitoring of potential safety risks.
Tallon said the strategy would guide the agency’s work with healthcare providers, researchers, industry and other partners to turn these developments into better outcomes for patients throughout the UK.
MHRA Chair Professor Anthony Harnden said closer cooperation across the healthcare and life sciences sectors would be essential to delivering the programme and accelerating access to safe and effective treatments.
Pharmaceutical industry welcomes regulatory reforms
The Association of the British Pharmaceutical Industry (ABPI) has welcomed the strategy, describing it as a significant step towards combining faster regulatory decisions with high standards of scientific scrutiny.
ABPI Chief Executive Richard Torbett said the industry had previously called for the MHRA to become a global leader in both regulating innovation and modernising its own regulatory processes.
He highlighted the strategy’s emphasis on speed, measurable performance targets, service guarantees and closer cooperation with the National Institute for Health and Care Excellence (NICE). The organisation expects these measures to help patients access new medicines earlier and strengthen the UK’s competitiveness in the global life sciences market.
Torbett said the industry looked forward to working with the regulator to turn the commitments into practical improvements.
The Health Research Authority (HRA) also welcomed the plans. Its Chief Executive, Dr Matt Westmore, said the two organisations had already made progress in modernising clinical trials legislation, strengthening safeguards for participants and reducing unnecessary administrative burdens on researchers.
The HRA, MHRA and Integrated Research Application System (IRAS) partners are also working to digitise the research approval process, with the aim of creating a more consistent journey from the initial application to patient recruitment.
Greater use of real-world data to strengthen patient safety
A central element of the strategy is to improve how the regulator collects, analyses and uses evidence about the safety and effectiveness of medicines and medical devices.
The MHRA intends to expand access to real-world information from hospitals and genomic research, recruit specialists with advanced analytical skills and use AI to identify emerging safety concerns earlier.
Working with the Health Data Research Service, the agency plans to strengthen real-time surveillance and improve the collection of information about medicines being investigated in clinical studies.
The regulator also intends to improve the monitoring and traceability of medical devices throughout their operational lifecycles. This should help it identify potential problems more quickly and establish which products may be affected.
Patients and healthcare professionals will also be able to report suspected adverse reactions and other safety concerns more easily through the MHRA’s Yellow Card reporting system.
The broader objective is to complement evidence generated during clinical trials with information gathered from routine healthcare, helping regulators assess how treatments perform in everyday clinical practice.
Shorter assessment times for clinical trials and medicines
The strategy includes several commitments to reduce regulatory waiting times for pharmaceutical developers and researchers.
The MHRA plans to introduce a premium service that would shorten the waiting period for scientific advice from 90 days to 45 days. This would give developers an opportunity to obtain regulatory guidance more quickly as they prepare medicines for assessment.
For qualifying Phase 1 clinical trials, the agency intends to halve its initial assessment target to 14 days.
The regulator will also seek to accelerate decisions on generic and biosimilar medicines. These products can expand treatment options and, where they provide cost-effective alternatives, help reduce expenditure across the NHS.
The proposed changes are intended to make the UK a more attractive location for clinical research and pharmaceutical investment while retaining the protections required for patients participating in trials.
AI and digital health to become central regulatory priorities
Artificial intelligence will play a prominent role in the MHRA’s plans for the coming years.
Among the proposed measures is an AI-enabled Clinical Trial Protocol Checker, designed to help research sponsors identify potential regulatory issues and submit higher-quality applications.
The agency will publish an AI Medicines Development Action Plan in 2027, setting out how artificial intelligence can be incorporated into the development of medicines.
It also plans to establish an MHRA Centre for AI and Digital Health. The centre will help clarify regulatory requirements for companies developing AI-powered medical devices, digital health products and medicines.
In parallel, the MHRA intends to create a modern and adaptable regulatory framework for AI as a medical device, reflecting the particular challenges posed by rapidly evolving technologies.
These initiatives are expected to support innovation while addressing questions of reliability, clinical evidence, risk assessment and patient protection.
Support for start-ups and advanced therapies
The strategy also seeks to remove barriers facing smaller life sciences companies and developers working on treatments for rare diseases.
A targeted voucher scheme is planned to help UK start-ups and smaller businesses navigate regulatory requirements. The MHRA will also pursue a more flexible, risk-proportionate framework for rare disease therapies, alongside efforts to strengthen links between genomic research, the NHS and the regulator.
Another priority is to encourage the development and adoption of new approach methodologies (NAMs), including organoids and other systems that can provide more human-relevant evidence. These approaches could help reduce reliance on animal models where scientifically appropriate alternatives are available.
By combining regulatory support with advances in genomics, biotechnology and research methods, the agency hopes to create better conditions for developing treatments for conditions that have historically received limited research attention.
Stronger action against illegal medicines
Alongside its innovation agenda, the MHRA intends to expand its capacity to investigate and prosecute illegal activity involving medicines and medical devices.
The regulator will strengthen criminal enforcement capabilities and work with social media companies and online marketplaces to tackle misleading information and prevent harmful products from reaching consumers.
The measures reflect concerns about the distribution of unlicensed or counterfeit medicines through online channels, where misleading claims can expose people to significant health risks.
The agency’s approach will combine enforcement with cooperation across digital platforms and other organisations involved in identifying and disrupting illegal sales.
International cooperation to reduce duplication
The MHRA also aims to strengthen its international influence and make it easier for innovative products to reach patients in multiple markets.
Planned measures include expanding reliance and recognition arrangements with trusted regulatory authorities, including cooperation with the US Food and Drug Administration (FDA). The agency also intends to continue recognising CE-marked medical devices under its applicable arrangements.
Through Regulatory Innovation Corridors, the MHRA plans to work with other national regulators to reduce duplicated assessments and help clinical research progress more efficiently.
The agency will also chair the Access Consortium, which brings together regulators from Australia, Canada, Singapore, Switzerland and the UK to support more efficient access to medicines.
An annual regulatory science conference is planned to bring together researchers, industry representatives and regulators, strengthening the UK's role in international discussions about emerging medical technologies and regulatory practice.
A long-term test of delivery
The MHRA’s 2030 Strategy sets out an ambition to combine scientific innovation, patient-centred decision-making and more efficient regulation. Its success will depend on whether the proposed reforms translate into faster access to effective treatments, stronger safety monitoring and a more predictable environment for researchers and companies.
The commitments also place greater emphasis on the diversity of clinical evidence, the participation of patients in regulatory decisions and the protection of people exposed to unsafe or illegally marketed products.
For the UK life sciences sector, the strategy offers a framework for adapting to rapid technological change while seeking to attract investment and research activity. For patients, its central promise is that advances in AI, personalised medicine and biotechnology will lead to safer, more effective and more accessible healthcare.
The coming years will show whether the agency can deliver these improvements while maintaining public confidence in the regulation of medicines and medical devices.
